Mechanisms of Leukocyte Distribution During Sepsis

Total Page:16

File Type:pdf, Size:1020Kb

Mechanisms of Leukocyte Distribution During Sepsis Ploppa et al. Critical Care 2010, 14:R201 http://ccforum.com/content/14/6/R201 RESEARCH Open Access Mechanisms of leukocyte distribution during sepsis: an experimental study on the interdependence of cell activation, shear stress and endothelial injury Annette Ploppa1, Volker Schmidt1, Andreas Hientz2, Joerg Reutershan1, Helene A Haeberle1, Boris Nohé1* Abstract Introduction: This study was carried out to determine whether interactions of cell activation, shear stress and platelets at sites of endothelial injury explain the paradoxical maldistribution of activated leukocytes during sepsis away from local sites of infection towards disseminated leukocyte accumulation at remote sites. Methods: Human umbilical venous endothelial cells (HUVEC) and polymorphonuclear neutrophils (PMN) were activated with lipopolysaccharide at 100 and 10 ng/ml to achieve adhesion molecule patterns as have been reported from the hyper- and hypo-inflammatory stage of sepsis. To examine effects of leukocyte activation on leukocyte-endothelial interactions, activated HUVEC were perfused with activated and non-activated neutrophils in a parallel plate flow chamber. Adhesion molecule expression and function were assessed by flow cytometry and blocking antibodies. In a subset of experiments the sub-endothelial matrix was exposed and covered with platelets to account for the effects of endothelial injury. To investigate interactions of these effects with flow, all experiments were done at various shear stress levels (3 to 0.25 dyne/cm2). Leukocyte-endothelial interactions were analyzed by videomicroscopy and analysis of covariance. Results: Activation of neutrophils rendered adhesion increasingly dependent on shear stress reduction. At normal shear stress, shedding of L-selectin decreased adhesion by 56%. Increased rolling fractions of activated PMN at low shear stress revealed impaired integrin affinity despite numerical up-regulation of CD11b. On sub-maximally activated, intact HUVEC shear stress became the prevailing determinant of adhesion. Presence of a platelet-covered injury with high surface density of P-selectin was the strongest variable for adhesion. When compared to maximally activated HUVEC, platelets increased neutrophil adhesion by 2.7-fold. At sub-maximal activation a 10-fold increase was observed (P < 0.05 for all). Conclusions: L-selectin shedding and integrin dysfunction render leukocyte adhesion increasingly susceptible to shear stress and alternative adhesion receptors. In combination, these effects inhibit recruitment to normally perfused sites with intact endothelium and favor maldistribution towards sites with compromised perfusion or endothelial injury. Introduction upregulation of endothelial adhesion molecules in Directing leukocytes to local sites of infection is a cru- inflamed tissue, resulting in a targeted accumulation of cial part of the innate immune response. While intravas- leukocytes at the site of infection [1]. Initially, selectin- cular shear forces prevent relevant leukocyte adhesion in dependent interactions overcome postcapillary shear a healthy individual, increased concentrations of micro- stress, enabling capture and rolling of leukocytes on the bial toxins and pro-inflammatory mediators induce activated endothelium. Selectin-interactions and local chemokines then activate leukocyte integrins such as * Correspondence: [email protected] lymphocyte function antigen-1 (LFA-1, CD11a/CD18) 1Department of Anesthesiology and Intensive Care Medicine, Tuebingen and macrophage antigen-1 (MAC-1, CD11b/CD18). University Hospital, Eberhard-Karls University, Hoppe-Seyler-Str. 3, Tuebingen, Local activation of integrins favours interactions with 72076, Germany Full list of author information is available at the end of the article endothelial counter-receptors, such as intercellular © 2010 Ploppa et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Ploppa et al. Critical Care 2010, 14:R201 Page 2 of 13 http://ccforum.com/content/14/6/R201 adhesion molecule-1 (ICAM-1), resulting in firm Boehringer, Mannheim, Germany) and cultured in adhesion [1]. Endothelial Cell Growth Medium (EGM™,PromoCell, In contrast to local inflammation, systemic sepsis is Heidelberg, Germany) on collagen-coated rectangular characterized by profound leukocyte activation through- coverslips (Falcon Biocoat™, Becton Dickinson Labware, out the circulation [2,3]. Because organ damage is attenu- Bedford, MA, USA). Confluent HUVEC of the first pas- ated by inhibiting leukocyte-endothelial interactions, sage were used for the experiments. systemic leukocyte activation and disseminated leukocyte PMN were isolated by density gradient centrifugation adhesion are regarded essential for septic organ dysfunc- at 1,700 rpm on a discontinuous Percoll gradient with tion [4-7]. In the last few years this traditional assump- 63% and 72% Percoll in buffer (Percoll, 1.130 g/ml; tion has been challenged by the finding of an impaired Amersham Pharmacia Biotech, Uppsala, Sweden). The chemotaxis and decreased rather than increased leuko- bottom layer was collected and contaminating erythro- cyte recruitment to local sites of infection in septic indi- cytes were removed by hypotonic lysis in 10% NH4Cl on viduals despite persistent upregulation of leukocyte ice. After washing, the PMN pellet was resuspended in integrins [2,3,8-10]. Moreover, it has been recognized cold Medium 199 (Sigma, St. Louis, MO, USA) supple- that systemic hyper-inflammation often turns into hypo- mented with 50% fetal calf serum (Gibco, Mannheim, inflammation with immunosuppressive cytokine-profiles Germany) at 5 × 107/ml. To avoid assay related activa- such as increased ratios of interleukin (IL)-10 and tumor tion of PMN during rewarming, we reconstituted the necrosis factor (TNF)-a [11-13]. Similar to the phenom- PMN pellet to 106 PMN/ml just before the adhesion enon of endotoxin tolerance, endothelial sensitivity to assay in normoxic, room temperature Medium 199 only. microbial toxins becomes altered and endothelial cell Final rewarming to 37°C was achieved in the heatable adhesion molecule expression is impaired [14-17]. Para- flow chamber. doxically these changes do not seem to protect patients from the development of endothelial cell damage and Adhesion assay leukocyte-related organ dysfunction since they are most PMN adhesion to HUVEC was quantified in a parallel pronounced in those with poor prognosis [12,13]. To plate flow chamber with a laminar flow profile (Rey- provide more insight into themechanismsthatcontri- nolds number <1, Figure 1) at 37°C as previously bute to these apparently paradoxical findings, we investi- reported [18]. According to those shear forces that have gated the following questions in a flow chamber model been observed in postcapillary venules of normal and with lipopolysaccharide induced inflammation. septic individuals we varied shear stress from 3 to 0.25 First, does systemic leukocyte activation increase or dyne/cm2 [19-25]. impair leukocyte recruitment to activated endothelium PMN were perfused over HUVEC-containing cover- and what are the mechanisms during the different stages slips for 10 minutes under different conditions of LPS- of inflammation? Second, if targeted leukocyte recruit- activation. Thereafter, PMN-adhesion was determined ment to locally activated endothelium is impaired, are from 10 s video recordings of five different fields of there mechanisms that favour disseminated leukocyte view by phase contrast microscopy (20× objective; accumulation at the same time? Third, given that later DMIRB, Leica, Bensheim, Germany). PMN were defined sepsis is characterized by immunosuppression, endothe- as rolling when traveling below 50% of the velocity of lial cell damage and organ dysfunction, are there free flowing PMN in close proximity to the endothelium mechanisms, independent of the physiological immune at the given shear stress [26]. A PMN, moving less than response, that gain a leading role for the distribution of one cell diameter in 10 s was defined to be firmly adher- leukocyte accumulation? ent. To exclude sedimentation artefacts, we exposed the adherent PMN, stepwise, up to 32 dyne/cm2 after the Materials and methods end of the adhesion experiment and measured cell Endothelial cell culture and leukocyte separation detachment. Under this exposure >70% of the adherent In compliance with the Helsinki Declaration on experi- PMN remained bound. As a measure for adhesion effi- mental research on humans and after obtaining ethical ciency [27,28], the rolling fraction was calculated as: committee approval (local ethics committee, University *(No. of rolling cells) × 100)/(No. of rolling cells + No. of of Tuebingen, reference numbers 315/99 and 69/2003- firmly adherent cells). Mean rolling velocities were A) and informed consent, human umbilical venous determined from more than 25 individual velocity pro- endothelial cells (HUVEC) and polymorphonuclear neu- files for each experimental condition as derived from trophils (PMN) were derived from human umbilical customized software for image recognition (CellTracker, veins and citrated blood samples from healthy volun- C. Zanke, University of Tuebingen, Germany). teers as previously described [18]. HUVEC were har- Selectin function was determined
Recommended publications
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Anti-CD18 / LFA1 Beta Antibody (ARG41484)
    Product datasheet [email protected] ARG41484 Package: 100 μl anti-CD18 / LFA1 beta antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes CD18 / LFA1 beta Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name CD18 / LFA1 beta Antigen Species Human Immunogen Recombinant protein of Human CD18 / LFA1 beta. Conjugation Un-conjugated Alternate Names MF17; LAD; CD antigen CD18; MFI7; MAC-1; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; LCAMB; Integrin beta-2; Complement receptor C3 subunit beta; LFA-1; CD18 Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse thymus Calculated Mw 85 kDa Observed Size ~ 98 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw www.arigobio.com 1/3 cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol ITGB2 Gene Full Name integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) Background This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers.
    [Show full text]
  • Atpase, Na+/K+ Transporting, Alpha 3 Polypeptide Homologous to 3'UTR
    HUGO ID Name Nalm-6 TOM-1 Reh Karpas-422 DoHH -2 SU-DHL-5 Namalwa DG-75 Ramos Raji BEL EHEB BONNA-12 L-428 DEL BCP-1 BC-3 BCBL-1 JSC-1 PEL-SY HBL-6 DS-1 RPMI-8226 NCI-H929 L-363 SK-MM-2 ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide CD24 homologous to 3'UTR of human CD24 gene ABCC5 multidrug resistance-associated protein (MRP5) CD72 CD72 antigen TCL1A Tcell leukemia/lymphoma 1 ITGB2 Integrin, beta 2 (antigen CD18 (p95)) ? nuclear ribonucleoprotein particle (hnRNP) SGT1 suppressor of G2 allele of skp1 homolog DNMT 1 DNA (cytosine-5-)-methyltransferase 1 GALE UDP-Galactose 4 epimerase (GALE) HADHSC L-3-hydroxyacyl-CoA dehydrogenase LIG4 DNA ligase IV LIG1 Ligase I, DNA, ATP-dependent CEBPG CCAA T/enhancer binding protein (C/EBP), gamma DCK Deoxycytidine kinase TCEA1 TRANSCRIPTION ELONGATION FACTOR S-II TCN 1 TRANSCOBALAMIN I PRECURSOR POLA2 DNA polymerase alpha subunit CCNG2 cyclin G2 RNPC1 Finkel-Biskis-Reilly murine sarcoma virus; Human seb4D RNPC1 Finkel-Biskis-Reilly murine sarcoma virus; Human seb4D DGKD Diacylglycerol kinase delta KIAA0220 Polycystic kidney disease protein 1 KIAA0220 calcium-dependent group X phospholipase A2 KIAA0220 calcium-dependent group X phospholipase A2 ALDH5A1 NAD+-dependent succinate-semialdehyde dehydrogenase CCNG2 Polycystic kidney disease 1 (autosomal dominant) PDCD4 nuclear antigen H731-like protein SSH3BP1 eps8 binding protein e3B1 MAP4K2 B lymphocyte serine/threonine protein kinase (GC kinase) MAPRE2 novel T-cell activation protein ZNFN1A Ikaros/LyF-1 homolog (hIk-1) FLJ22624 clone 23799 KIAA0355
    [Show full text]
  • Rabbit Anti-Phospho-CD18-SL10462R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-Phospho-CD18 SL10462R-FITC Product Name: Anti-Phospho-CD18 (Thr758)/FITC Chinese Name: FITC标记的磷酸化整合素β2/Integrin β2抗体 CD18 (Phospho Thr758); CD18 (Phospho-Thr758); CD18 (Phospho T758); p-CD18 (T758); p-CD18 (Thr758); Integrin beta 2; 95 subunit beta; CD 18; CD18; Cell surface adhesion glycoprotein LFA 1/CR3/P150,959 beta subunit precursor); Cell surface adhesion glycoproteins LFA 1/CR3/p150,95 subunit beta; Cell surface adhesion glycoproteins LFA-1/CR3/p150; Complement receptor C3 beta subunit; Complement Alias: receptor C3 subunit beta; Integrin beta chain beta 2; Integrin beta-2; Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); ITB2_HUMAN; ITGB2; LAD; LCAMB; Leukocyte associated antigens CD18/11A, CD18/11B, CD18/11C; Leukocyte cell adhesion molecule CD18; LFA 1; LFA1; Lymphocyte function associated antigen 1; MAC 1; MAC1; MF17; MFI7; OTTHUMP00000115278; OTTHUMP00000115279; OTTHUMP00000115280; OTTHUMP00000115281; OTTHUMP00000115282. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Dog,Pig,Cow,Horse,Rabbit,Sheep,Guinea Pig, Flow-Cyt=1:50-200ICC=1:50-200IF=1:50-200www.sunlongbiotech.com Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 82kDa Form: Lyophilized or Liquid Concentration: 1mg/ml KLH conjugated synthesised phosphopeptide derived from human CD18 around the immunogen: phosphorylation site of Thr758 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year.
    [Show full text]
  • Immuno-Oncology Panel 4 (Direct-MRM MS, Pending)
    Immuno-Oncology panel 4 (direct-MRM MS, pending) (397 analytes pending validation) Gene Symbol Target protein name UniProt ID (& link) Modification* *blanks mean the assay detects the ABCE1 ATP-binding cassette sub-family E member 1 P61221 non-modified peptide sequence ABCE1 ATP-binding cassette sub-family E member 1 P61221 ABI1 Abl interactor 1 Q8IZP0 ABI1 Abl interactor 1 Q8IZP0 AKT1 RAC-alpha serine/threonine-protein kinase P31749 AKT1 RAC-alpha serine/threonine-protein kinase P31749 ANXA1 Annexin A1 P04083 ANXA4 annexin A4 P09525 ANXA5 Annexin A5 P08758 ANXA5 Annexin A5 P08758 ANXA6 annexin A6 P08133 B2M Beta-2-microglobulin P61769 B2M Beta-2-microglobulin P61769 BCAP31 B-cell receptor-associated protein 31 P51572 BCAP31 B-cell receptor-associated protein 31 P51572 BCL2 Apoptosis regulator Bcl-2 P10415 BCL2L1 Bcl-2-like protein 1 Q07817 BCL2L11 Bcl-2-like protein 11 O43521 BCL2L11 Bcl-2-like protein 11 O43521 BCL2L2 Bcl-2-like protein 2 Q92843 BCL2L2 Bcl-2-like protein 2 Q92843 BCL3 B-cell lymphoma 3 protein P20749 BCL3 B-cell lymphoma 3 protein P20749 BID BH3-interacting domain death agonist P55957 BID BH3-interacting domain death agonist P55957 BNIP3L BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like O60238 BNIP3L BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like O60238 BPGM Bisphosphoglycerate mutase P07738 BPGM Bisphosphoglycerate mutase P07738 BST2 Bone marrow stromal antigen 2 Q10589 BST2 Bone marrow stromal antigen 2 Q10589 C1QA Complement C1q subcomponent subunit A P02745 C1QA Complement C1q subcomponent
    [Show full text]
  • Cell Adhesion Molecules in Normal Skin and Melanoma
    biomolecules Review Cell Adhesion Molecules in Normal Skin and Melanoma Cian D’Arcy and Christina Kiel * Systems Biology Ireland & UCD Charles Institute of Dermatology, School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland; [email protected] * Correspondence: [email protected]; Tel.: +353-1-716-6344 Abstract: Cell adhesion molecules (CAMs) of the cadherin, integrin, immunoglobulin, and selectin protein families are indispensable for the formation and maintenance of multicellular tissues, espe- cially epithelia. In the epidermis, they are involved in cell–cell contacts and in cellular interactions with the extracellular matrix (ECM), thereby contributing to the structural integrity and barrier for- mation of the skin. Bulk and single cell RNA sequencing data show that >170 CAMs are expressed in the healthy human skin, with high expression levels in melanocytes, keratinocytes, endothelial, and smooth muscle cells. Alterations in expression levels of CAMs are involved in melanoma propagation, interaction with the microenvironment, and metastasis. Recent mechanistic analyses together with protein and gene expression data provide a better picture of the role of CAMs in the context of skin physiology and melanoma. Here, we review progress in the field and discuss molecular mechanisms in light of gene expression profiles, including recent single cell RNA expression information. We highlight key adhesion molecules in melanoma, which can guide the identification of pathways and Citation: D’Arcy, C.; Kiel, C. Cell strategies for novel anti-melanoma therapies. Adhesion Molecules in Normal Skin and Melanoma. Biomolecules 2021, 11, Keywords: cadherins; GTEx consortium; Human Protein Atlas; integrins; melanocytes; single cell 1213. https://doi.org/10.3390/ RNA sequencing; selectins; tumour microenvironment biom11081213 Academic Editor: Sang-Han Lee 1.
    [Show full text]
  • PDF Download
    Integrin β2 Polyclonal Antibody Catalog No : YT2369 Reactivity : Human,Mouse,Rat Applications : IF/ICC,ELISA Gene Name : ITGB2 Protein Name : Integrin beta-2 Human Gene Id : 3689 Human Swiss Prot P05107 No : Mouse Gene Id : 16414 Mouse Swiss Prot P11835 No : Immunogen : The antiserum was produced against synthesized peptide derived from human CD18/ITGB2. AA range:720-769 Specificity : Integrin β2 Polyclonal Antibody detects endogenous levels of Integrin β2 protein. Formulation : Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Source : Rabbit Dilution : Immunofluorescence: 1/200 - 1/1000. ELISA: 1/5000. Not yet tested in other applications. Purification : The antibody was affinity-purified from rabbit antiserum by affinity- chromatography using epitope-specific immunogen. Concentration : 1 mg/ml Storage Stability : -20°C/1 year Molecularweight : 84782 1 / 2 Cell Pathway : Cell adhesion molecules (CAMs),Natural killer cell mediated cytotoxicity,Leukocyte transendothelial migration,Regulates Actin and Cytoskeleton,Viral myocarditis, Background : integrin subunit beta 2(ITGB2) Homo sapiens This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers. Integrins are integral cell-surface proteins that participate in cell adhesion as well as cell-surface mediated signalling. The encoded protein plays an important role in immune response and defects in this gene cause leukocyte adhesion deficiency. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014], Function : disease:Defects in ITGB2 are the cause of leukocyte adhesion deficiency type I (LAD1) [MIM:116920]. LAD1 patients have recurrent bacterial infections and their leukocytes are deficient in a wide range of adhesion-dependent functions.,function:Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4.
    [Show full text]
  • Recombinant Mouse Integrin Alpha X Beta 2, CF Datasheet Catalog Number: PR15089CF Product Type: Recombinant Protein
    Recombinant Mouse Integrin alpha x beta 2, CF Datasheet Catalog Number: PR15089CF Product Type: Recombinant Protein Source: Chinese Hamster Ovary cell line, CHO- derived mouse Integrin alpha X beta 2 protein. Description: Integrin alpha X beta 2, also called CD11c/CD18, p150/95 or complement receptor type 4 (CR4), is one of four beta 2 integrins. The non-covalent heterodimer of 150 kDa alpha X/CD11c and 95 kDa beta 2/CD18 integrin subunits is commonly used as a marker for dendritic cells (DC) and classically activated macrophages (M1), but is also expressed on hairy cell leukemias, with lower amounts on other myeloid cells and activated B, NK and some cytotoxic T cells. Inflammation enhances surface expression of alpha X beta 2 in states such as obesity (adipose DC), asthma (lung DC) and hypertriglyceridemia (circulating monocytes), increasing the adhesive capacity of the cells and contributing to pathology. The alpha X vWFA or I‑domain, which contains the adhesion sites, forms the N‑terminal head region with the alpha X beta-propeller and the beta 2 vWFA domain. Molecular Mass: 131 kDa (Integrin alpha X) & 83 kDa (Integrin beta 2) Purity: Greater than 95.0% as determined by: (a) Analysis by SDS-PAGE. Biological Activity: Measured by the ability of the immobilized protein to support adhesion of J45.01 human acute lymphoblastic leukemia T lymphocytes. The ED50 for this effect is 0.2-1.0 μg/mL. Format: Lyophilized from a 0.2 μm filtered solution in PBS. Reconstitution: Reconstitute at 100 μg/mL in PBS. Storage: This product can be stored for up to 1 month at 2°C to 8°C under sterile condition after reconstitution, for up to 3 months at -20°C to -70°C under sterile condition after reconstitution, or for up to 12 months at -20°C to -70°C as supplied.
    [Show full text]
  • Review Integrins: Bidirectional, Allosteric Signaling Machines
    Cell, Vol. 110, 673–687, September 20, 2002, Copyright 2002 by Cell Press Integrins: Bidirectional, Review Allosteric Signaling Machines Richard O. Hynes1 and Hynes, 2002). The simplest metazoa, sponges and Howard Hughes Medical Institute cnidaria, have integrins (Burke, 1999; Hughes, 2001) and Center for Cancer Research it is clear that primitive bilateria had at least two integrin Department of Biology ␣␤ heterodimers, the descendents of which persist to Massachusetts Institute of Technology this day in organisms as diverse as flies, nematodes, Cambridge, Massachusetts 02139 and vertebrates (Hynes and Zhao, 2000). Indeed, that is the entire set of integrins in Caenorhabditis elegans; one ␤ subunit and two ␣ subunits forming two integrins. In their roles as major adhesion receptors, integrins Orthologs of these two integrins are recognized in Dro- signal across the plasma membrane in both directions. sophila melanogaster and in vertebrates, although ver- Recent structural and cell biological data suggest tebrates have expanded each set (Figure 1). One set models for how integrins transmit signals between (blue in Figure 1) recognizes the tripeptide sequence, their extracellular ligand binding adhesion sites and RGD, in molecules such as fibronectin and vitronectin their cytoplasmic domains, which link to the cytoskel- in vertebrates and tiggrin in Drosophila, whereas the eton and to signal transduction pathways. Long-range other set (purple in Figure 1) mediates adhesion to base- conformational changes couple these functions via ment membrane laminins. It is plausible that evolution allosteric equilibria. of integrins was necessary to allow the cell-matrix adhe- sion intrinsic to metazoa, and as diploblastic organisms Integrins are the major metazoan receptors for cell adhe- evolved, the two cell layers may have evolved separate sion to extracellular matrix proteins and, in vertebrates, integrins to mediate their asymmetric interactions with also play important roles in certain cell-cell adhesions.
    [Show full text]
  • Anti-CD18 / LFA-1 Beta Antibody [MEM-148] (PE) (ARG53781)
    Product datasheet [email protected] ARG53781 Package: 100 tests anti-CD18 / LFA-1 beta antibody [MEM-148] (PE) Store at: 4°C Summary Product Description RPE-conjugated Mouse Monoclonal antibody [MEM-148] recognizes CD18 Tested Reactivity Hu Tested Application FACS Specificity The clone MEM-148 recognizes an epitope on CD18 which is essentially inaccessible in intact integrin molecules on resting leukocytes, but is exposed on high-affinity state of LFA-1 or on unassociated CD18. CD18 (integrin beta2 subunit; beta2 integrin) is a 90-95 kDa type I transmembrane protein expressed on all leukocytes. HLDA VI; WS Code AS A052 Host Mouse Clonality Monoclonal Clone MEM-148 Isotype IgG1 Target Name CD18 / LFA-1 beta Immunogen Peripheral blood mononuclear cells Conjugation RPE Full Name integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) Alternate Names MF17; LAD; CD antigen CD18; MFI7; MAC-1; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; LCAMB; Integrin beta-2; Complement receptor C3 subunit beta; LFA-1; CD18 Application Instructions Species Does Not React With Pig Application table Application Dilution FACS 20 µl / 10^6 cells Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Properties Form Liquid Purification Note The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary. Buffer PBS, 15 mM Sodium azide and 0.2% (w/v) high-grade protease free BSA Preservative 15 mM Sodium azide Stabilizer 0.2% (w/v) high-grade protease free BSA www.arigobio.com 1/2 Storage instruction Aliquot and store in the dark at 2-8°C.
    [Show full text]
  • Gene Expression Targets
    Supplementary Table S1: Gene expression targets Cell Functional Probe ID Gene ID Gene Descriptions type Category Antigen-dependent activation MmugDNA.32422.1.S1_at CD180 CD180 molecule B 1 MmugDNA.18254.1.S1_at CD19 CD19 molecule B 1 MmugDNA.14306.1.S1_at CD1C CD1c molecule B 1 MmugDNA.20774.1.S1_at CD274 CD274 molecule B 1 MmugDNA.19231.1.S1_at CD28 CD28 molecule B 1 MmuSTS.3490.1.S1_at CD72 CD72 molecule B 1 MmugDNA.37827.1.S1_at CD79B CD79b molecule, immunoglobulin- associated beta B 1 MmugDNA.29916.1.S1_at CD80 CD80 molecule B 1 MmugDNA.6430.1.S1_at CD83 CD83 molecule B 1 MmugDNA.32699.1.S1_at CD86 CD86 molecule B 1 MmugDNA.19832.1.S1_at CIITA class II, major histocompatibility complex, transactivator B 1 MmuSTS.3942.1.S1_at CR2 complement component receptor 2 B 1 MmugDNA.25496.1.S1_at CTLA4 cytotoxic T-lymphocyte-associated protein 4 B 1 MmugDNA.5901.1.S1_at FAS Fas cell surface death receptor B 1 MmugDNA.8857.1.S1_at FASLG Fas ligand (TNF superfamily, member 6) B 1 MmugDNA.27012.1.S1_at FKBP2 FK506 binding protein 2, 13kDa P 1 MmugDNA.38565.1.S1_at FOS FBJ murine osteosarcoma viral oncogene homolog B 1 MmuSTS.165.1.S1_at ID3 inhibitor of DNA binding 3 B 1 MmugDNA.20492.1.S1_at IGBP1 immunoglobulin (CD79A) binding protein 1 B 1 MmugDNA.2488.1.S1_at IGHD immunoglobulin heavy constant delta B 1 MmuSTS.4350.1.S1_at IGHM immunoglobulin heavy constant mu B 1 MmunewRS.438.1.S1_at IL2 interleukin 2 B 1 MmugDNA.42882.1.S1_x_at SPN sialophorin B,P 1 MmuSTS.4526.1.S1_at SYK spleen tyrosine kinase B 1 MmuSTS.4672.1.S1_at TNF tumor necrosis factor
    [Show full text]
  • Novel Protein Pathways in Development and Progression of Pulmonary Sarcoidosis Maneesh Bhargava1*, K
    www.nature.com/scientificreports OPEN Novel protein pathways in development and progression of pulmonary sarcoidosis Maneesh Bhargava1*, K. J. Viken1, B. Barkes2, T. J. Grifn3, M. Gillespie2, P. D. Jagtap3, R. Sajulga3, E. J. Peterson4, H. E. Dincer1, L. Li2, C. I. Restrepo2, B. P. O’Connor5, T. E. Fingerlin5, D. M. Perlman1 & L. A. Maier2 Pulmonary involvement occurs in up to 95% of sarcoidosis cases. In this pilot study, we examine lung compartment-specifc protein expression to identify pathways linked to development and progression of pulmonary sarcoidosis. We characterized bronchoalveolar lavage (BAL) cells and fuid (BALF) proteins in recently diagnosed sarcoidosis cases. We identifed 4,306 proteins in BAL cells, of which 272 proteins were diferentially expressed in sarcoidosis compared to controls. These proteins map to novel pathways such as integrin-linked kinase and IL-8 signaling and previously implicated pathways in sarcoidosis, including phagosome maturation, clathrin-mediated endocytic signaling and redox balance. In the BALF, the diferentially expressed proteins map to several pathways identifed in the BAL cells. The diferentially expressed BALF proteins also map to aryl hydrocarbon signaling, communication between innate and adaptive immune response, integrin, PTEN and phospholipase C signaling, serotonin and tryptophan metabolism, autophagy, and B cell receptor signaling. Additional pathways that were diferent between progressive and non-progressive sarcoidosis in the BALF included CD28 signaling and PFKFB4 signaling. Our studies demonstrate the power of contemporary proteomics to reveal novel mechanisms operational in sarcoidosis. Application of our workfows in well-phenotyped large cohorts maybe benefcial to identify biomarkers for diagnosis and prognosis and therapeutically tenable molecular mechanisms.
    [Show full text]